Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript [Seeking Alpha]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Seeking Alpha
Company Participants Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Conference Call Participants Jordan Feld Anthony Martinez Nancy Reau Eric Lawitz Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good morning, and welcome to the Atea Pharmaceuticals Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Atea website following the conclusion of the event. I'd now like to turn the call over to Dr. Jean-Pierre Sommadossi, Founder, Chairman and Chief Executive Officer of Atea Pharmaceuticals. Please go ahead, JP. Jean-Pierre Sommadossi Founder, Chairman, CEO & President Thank you, Tara. Good morning, everyone. I'm JP Sommadoss
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Atea Pharmaceuticals GAAP EPS of -$0.53 misses by $0.09 [Seeking Alpha]Seeking Alpha
AVIR
Earnings
- 11/12/25 - Miss
AVIR
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- AVIR's page on the SEC website